Company Profile
REGENXBIO Inc. Stock Price, News & Catalysts
- Ticker:
- RGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.45 USD (-3.99%)
Close
Last updated: October 6, 2026
337M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, RGNX closed down 3.99% at $7.45. No new same-company headline was identified in the current news window.
Company overview
AAV Gene Therapy Company
REGENXBIO develops gene therapies based on its NAV adeno-associated virus platform. The company combines internally developed clinical programs with partnered products that can generate license fees, milestones, and royalties.
Duchenne Muscular Dystrophy Program
RGX-202 is a systemic gene therapy designed to deliver a differentiated microdystrophin transgene for Duchenne muscular dystrophy. The program is being advanced toward a rolling biologics license application and a confirmatory ex-U.S. development plan.
Retinal Gene Therapy Collaboration
Surabgene lomparvovec, also known as ABBV-RGX-314, is being developed with AbbVie for wet age-related macular degeneration and diabetic retinopathy. The program uses in-office suprachoroidal delivery and late-stage studies intended to reduce dependence on frequent anti-VEGF injections.
Lysosomal Storage Disease Portfolio
NAVSUNLI, formerly RGX-121, is a gene therapy for Hunter syndrome, while RGX-111 targets mucopolysaccharidosis type I. These programs use CNS-directed delivery to address neurological manifestations that are difficult to treat with systemic enzyme replacement.
Platform Licensing and Royalties
REGENXBIO's NAV vectors are used in partnered therapies, including approved gene therapies such as Zolgensma and Itvisma. This licensing model provides diversified economics and external validation while the company funds a narrower set of wholly owned programs.
Future catalysts
- Initiation of the rolling BLA submission for RGX-202 in Duchenne muscular dystrophy in the third quarter of 2026.
- Initiation of the ex-U.S. AFFINITY RISE confirmatory study of RGX-202 in the first half of 2027.
- Topline results from the ATMOSPHERE and ASCENT pivotal studies of surabgene lomparvovec in wet age-related macular degeneration in the fourth quarter of 2026.
- Global regulatory submissions for surabgene lomparvovec in 2027.
- Resubmission of the NAVSUNLI BLA for Hunter syndrome in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of REGENXBIO Inc. (RGNX)?
REGENXBIO Inc. (RGNX) most recently closed at 7.45 USD, a -3.99% move versus the previous session.
What is the market cap of REGENXBIO Inc. (RGNX)?
REGENXBIO Inc. currently has a market capitalization of 337M USD on BioPharmSignal.
What does REGENXBIO Inc. do?
AAV Gene Therapy Company REGENXBIO develops gene therapies based on its NAV adeno-associated virus platform. The company combines internally developed clinical programs with partnered products that can generate license fees, milestones, and royalties. Duchenne Muscular Dystrophy Program RGX-202 is a systemic gene therapy designed to deliver a differentiated...
On which exchange is RGNX stock listed?
REGENXBIO Inc. (RGNX) is associated with NASDAQ, United States, Biopharma.
What is RGX-202?
Initiation of the rolling BLA submission for RGX-202 in Duchenne muscular dystrophy in the third quarter of 2026.
Which conditions is REGENXBIO Inc. targeting with RGX-202?
Initiation of the rolling BLA submission for RGX-202 in Duchenne muscular dystrophy in the third quarter of 2026.
How does REGENXBIO Inc. describe recent progress with RGX-202?
Initiation of the rolling BLA submission for RGX-202 in Duchenne muscular dystrophy in the third quarter of 2026.
What is ABBV-RGX-314?
Retinal Gene Therapy Collaboration Surabgene lomparvovec, also known as ABBV-RGX-314, is being developed with AbbVie for wet age-related macular degeneration and diabetic retinopathy.